IRX-101

DRUG3 trials

Sponsors

iRenix Medical, Inc.

Conditions

Branch Retinal Vein OcclusionDiabetic Macular EdemaGlaucoma/Closed Angle GlaucomaRetinal Disease

Phase 2

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)

CompletedNCT05747430

iRenix Medical, Inc.Retinal Disease

Start: 2023-02-22End: 2026-03-31Updated: 2026-04-03

Phase 3

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

TerminatedNCT05127525

iRenix Medical, Inc.Branch Retinal Vein Occlusion, Diabetic Macular Edema, Glaucoma/Closed Angle Glaucoma

Start: 2021-11-15End: 2022-01-31Updated: 2022-05-24

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

Not yet recruitingNCT05750589

iRenix Medical, Inc.Retinal Disease

Start: 2026-09-01End: 2027-12-31Target: 240Updated: 2026-04-03